Akari Therapeutics (NASDAQ:AKTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a strong sell rating to a sell rating in a research report sent to investors on Saturday.

A number of other brokerages also recently weighed in on AKTX. Maxim Group raised shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Monday, July 20th. Weiss Ratings upgraded shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Akari Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.33.

Akari Therapeutics Stock Down 4.8%

NASDAQ:AKTX opened at $7.47 on Friday. The business’s 50-day moving average price is $9.81 and its two-hundred day moving average price is $8.94. Akari Therapeutics has a twelve month low of $3.02 and a twelve month high of $49.60.

Hedge Funds Weigh In On Akari Therapeutics

A hedge fund recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC bought a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics at the end of the most recent reporting period. 5.06% of the stock is currently owned by institutional investors and hedge funds.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.